Harbor Investment Advisory’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Harbor Investment Advisory’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-572	Closed	-$7.68K	–	1384
2023 Q1	$7.68K	Hold	572	–	–	﹤0.01%	1064
2022 Q4	$7.08K	Hold	572	–	–	﹤0.01%	1062
2022 Q3	$8K	Hold	572	–	–	﹤0.01%	1075
2022 Q2	$8K	Hold	572	–	–	﹤0.01%	1080
2022 Q1	$9K	Hold	572	–	–	﹤0.01%	1081
2021 Q4	$9K	Hold	572	–	–	﹤0.01%	1086
2021 Q3	$8K	Hold	572	–	–	﹤0.01%	1101
2021 Q2	$11K	Hold	572	–	–	﹤0.01%	1011
2021 Q1	$13K	Hold	572	–	–	﹤0.01%	945
2020 Q4	$14K	Buy	572 +179	+46%	+$5.93K	﹤0.01%	883
2020 Q3	$16K	Buy	393 +195	+98%	+$8.96K	﹤0.01%	790
2020 Q2	$9K	Hold	198	–	–	﹤0.01%	805
2020 Q1	$12K	Buy	+198	New	+$17.8K	﹤0.01%	709

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Harbor Investment Advisory's ICPT Position: Q2 2023 in Review

Harbor Investment Advisory sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 572 shares — an estimated $7.68K sold.

Harbor Investment Advisory first reported a position in ICPT in Q1 2020 and held it in 13 quarters. The position peaked at $16K in Q3 2020. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Harbor Investment Advisory reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Harbor Investment Advisory sold 572 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $7.68K.
Harbor Investment Advisory first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2020 and held it in 13 quarters.
Harbor Investment Advisory's Intercept Pharmaceuticals, Inc. position peaked at $16K in Q3 2020.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Harbor Investment Advisory's 13F filing for Q2 2023, filed 14 Jul 2023.